Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Exact Sciences Corporation or Insmed Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Exact Sciences Corporation and Insmed Incorporated compare based on key financial metrics to determine which better meets your investment needs.
About Exact Sciences Corporation and Insmed Incorporated
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Latest Biotechnology and Exact Sciences Corporation, Insmed Incorporated Stock News
As of May 7, 2025, Exact Sciences Corporation had a $10.1 billion market capitalization, compared to the Biotechnology median of $104.9 million. Exact Sciences Corporation’s stock is NA in 2025, NA in the previous five trading days and down 14.16% in the past year.
Currently, Exact Sciences Corporation does not have a price-earnings ratio. Exact Sciences Corporation’s trailing 12-month revenue is $2.8 billion with a -36.1% net profit margin. Year-over-year quarterly sales growth most recently was 10.9%. Analysts expect adjusted earnings to reach $0.225 per share for the current fiscal year. Exact Sciences Corporation does not currently pay a dividend.
Currently, Insmed Incorporated does not have a price-earnings ratio. Insmed Incorporated’s trailing 12-month revenue is $363.7 million with a -251.2% net profit margin. Year-over-year quarterly sales growth most recently was 24.7%. Analysts expect adjusted earnings to reach $-5.323 per share for the current fiscal year. Insmed Incorporated does not currently pay a dividend.
How We Compare Exact Sciences Corporation and Insmed Incorporated Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Exact Sciences Corporation and Insmed Incorporated’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions